{"id":67946,"date":"2025-10-03T07:00:43","date_gmt":"2025-10-03T07:00:43","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=67946"},"modified":"2026-04-30T10:23:26","modified_gmt":"2026-04-30T10:23:26","slug":"bdenza","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/bdenza\/","title":{"rendered":"Bdenza"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Bdenza?<\/h3>\n<p style=\"margin:0;\"><strong>Bdenza<\/strong> is an oral tablet from Beacon Pharmaceuticals containing <strong>enzalutamide 40 mg<\/strong> &mdash; a <strong>second-generation androgen-receptor signalling inhibitor<\/strong>. Pou\u017e\u00edv\u00e1 se na <strong>metastatic castration-resistant prostate cancer (mCRPC)<\/strong>, <strong>non-metastatic CRPC<\/strong> a <strong>metastatic hormone-sensitive prostate cancer<\/strong>. Standard dose: <strong>160 mg once daily (4 &times; 40 mg tablets)<\/strong>, with or without food. More potent than first-generation anti-androgens (bicalutamide, flutamide) and active in castration-resistant disease where they fail. <strong>Seizure risk &mdash; avoid in patients with history of seizures.<\/strong> Other key risks: hypertension, fatigue, falls\/fractures, cognitive effects, posterior reversible encephalopathy syndrome (rare). Continue concurrent LHRH agonist throughout treatment. Mandatory monitoring: BP at baseline + at each visit, periodic LFTs + FBC.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Vy\u017eaduje se odborn\u00fd dohled.<\/strong> L\u00e9ky na rakovinu mus\u00ed b\u00fdt p\u0159edeps\u00e1ny o\u0161et\u0159uj\u00edc\u00edm onkologem s potvrzenou diagn\u00f3zou, vstupn\u00edm stagingem a definovan\u00fdm l\u00e9\u010debn\u00fdm pl\u00e1nem. Nikdy neza\u010d\u00ednejte, nep\u0159eru\u0161ujte, nem\u011b\u0148te d\u00e1vkov\u00e1n\u00ed ani neu\u017e\u00edvejte l\u00e9ky na rakovinu mimo onkologick\u00fd l\u00e9\u010debn\u00fd pl\u00e1n. V\u011bt\u0161ina l\u00e9k\u016f na rakovinu vy\u017eaduje pravideln\u00e9 monitorov\u00e1n\u00ed krevn\u00edch test\u016f (krevn\u00ed obraz, jatern\u00ed testy, funkce ledvin), je absolutn\u011b kontraindikov\u00e1na v t\u011bhotenstv\u00ed a m\u00e1 v\u00fdznamn\u00e9 l\u00e9kov\u00e9 interakce.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 \u0160ifrovan\u00e9 platby<\/strong> \u00b7 <strong>\ud83d\udcb3 Ov\u011b\u0159en\u00fd platebn\u00ed procesor<\/strong> \u00b7 <strong>\ud83d\ude9a Doprava do cel\u00e9ho sv\u011bta<\/strong> \u00b7 <strong>\u2b50 4,9\/5 od 1 400+ z\u00e1kazn\u00edk\u016f<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">What Is Bdenza?<\/h2>\n<p>Bdenza is an oral tablet from Beacon Pharmaceuticals containing <strong>enzalutamide 40 mg<\/strong>. Enzalutamide is a <strong>second-generation androgen-receptor (AR) signalling inhibitor<\/strong> &mdash; mechanistically distinct from the first-generation anti-androgens (bicalutamide, flutamide). It is licensed for: <strong>metastatic castration-resistant prostate cancer (mCRPC)<\/strong> in chemotherapy-na&iuml;ve and post-docetaxel patients; <strong>non-metastatic CRPC<\/strong> with rapidly rising PSA; and <strong>metastatic castration-sensitive prostate cancer (mHSPC)<\/strong> with concurrent ADT.<\/p>\n<h2 class=\"wp-block-heading\">How Does Bdenza Work?<\/h2>\n<p>Enzalutamide is a triple-action AR signalling inhibitor:<\/p>\n<ul>\n<li><strong>Competitive AR binding<\/strong> with much higher affinity than first-generation anti-androgens.<\/li>\n<li><strong>Inhibits AR nuclear translocation<\/strong> &mdash; even when bound by androgen, prevents the receptor from entering the nucleus.<\/li>\n<li><strong>Inhibits AR-DNA binding<\/strong> &mdash; even if AR enters the nucleus, prevents binding to androgen-response elements on target genes.<\/li>\n<\/ul>\n<p>This triple mechanism makes enzalutamide active in <strong>castration-resistant prostate cancer<\/strong>, where AR overexpression and AR-splice variants make first-generation anti-androgens ineffective.<\/p>\n<h2 class=\"wp-block-heading\">Pou\u017eit\u00ed a indikace<\/h2>\n<ul>\n<li><strong>Metastatic castration-resistant prostate cancer (mCRPC)<\/strong> &mdash; chemotherapy-na&iuml;ve (PREVAIL) and post-docetaxel (AFFIRM)<\/li>\n<li><strong>Non-metastatic CRPC with PSA doubling time &lt; 10 months<\/strong> (PROSPER)<\/li>\n<li><strong>Metastatic hormone-sensitive prostate cancer (mHSPC)<\/strong> with ADT (ARCHES, ENZAMET)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bdenza Dosage and How to Take<\/h2>\n<p>Standardn\u00ed d\u00e1vka: <strong>160 mg once daily (4 &times; 40 mg tablets) at the same time each day<\/strong>, s j\u00eddlem nebo bez j\u00eddla.<\/p>\n<ol>\n<li>Swallow tablets whole with water. Do NOT chew, dissolve or split.<\/li>\n<li>Continue concurrent LHRH agonist therapy throughout enzalutamide treatment unless surgically castrated.<\/li>\n<li><strong>Povinn\u00e9 monitorov\u00e1n\u00ed:<\/strong> blood pressure at baseline and each clinic visit; LFTs and FBC periodically; PSA every 3 months.<\/li>\n<li><strong>Falls and fracture prevention:<\/strong> elderly patients have increased fall and fracture risk on enzalutamide. Bone health assessment, calcium + vitamin D, consider bisphosphonate.<\/li>\n<li><strong>Dose modifications<\/strong> for moderate hepatic impairment, severe adverse events, or grade &ge; 3 toxicity: reduce to 80 or 120 mg\/day under specialist guidance.<\/li>\n<li>Nep\u0159eru\u0161ujte l\u00e9\u010dbu bez pokyn\u016f onkologa.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Side Effects of Bdenza<\/h2>\n<p><strong>\u010cast\u00e9:<\/strong> fatigue (the dominant side effect), hot flushes, hypertension, fall and fracture risk (elderly), arthralgia, headache, dizziness, decreased weight, anxiety, insomnia.<\/p>\n<p><strong>D\u016fle\u017eit\u00e9:<\/strong><\/p>\n<ul>\n<li><strong>Seizures (&lt; 1% in trials)<\/strong> &mdash; lower seizure threshold; avoid in any patient with seizure history or on drugs lowering seizure threshold<\/li>\n<li>Cognitive effects: memory difficulties, concentration impairment<\/li>\n<li>Hypertension &mdash; new-onset or worsening; treat aggressively<\/li>\n<li>Posterior reversible encephalopathy syndrome (PRES) &mdash; rare but documented; new-onset severe headache, confusion, vision changes, seizures<\/li>\n<li>Hepatotoxicity (mild LFT rises common; severe rare)<\/li>\n<li>Neutropenia, anaemia<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Varov\u00e1n\u00ed a opat\u0159en\u00ed<\/h2>\n<ul>\n<li><strong>Seizure history (any type):<\/strong> avoid enzalutamide. If essential, specialist neurology + oncology supervision.<\/li>\n<li><strong>Drugs that lower seizure threshold<\/strong> (bupropion, clozapine, tramadol, fluoroquinolones, theophylline): caution.<\/li>\n<li><strong>Falls and fracture risk:<\/strong> bone health assessment, supportive care.<\/li>\n<li><strong>Hypertenze:<\/strong> baseline + ongoing BP monitoring.<\/li>\n<li><strong>T\u011b\u017ek\u00e9 jatern\u00ed po\u0161kozen\u00ed (Child-Pugh C):<\/strong> nedoporu\u010duje se.<\/li>\n<li><strong>PRES symptoms:<\/strong> new severe headache, vision change, confusion &mdash; stop and seek same-day review.<\/li>\n<li><strong>Pregnancy \/ fertility:<\/strong> male-only indication. Use condom + contraception with female partners of childbearing potential during treatment + 3 months after.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Kombinujte s<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">\u00da\u010dinek<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Co d\u011blat<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP2C8 inhibitors (gemfibrozil)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise enzalutamide levels &mdash; toxicity risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce enzalutamide to 80 mg\/day if combination unavoidable.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John&#39;s wort)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Lower enzalutamide levels &mdash; treatment failure<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid. If unavoidable, increase to 240 mg\/day under specialist guidance.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin and other CYP2C9 \/ CYP3A4 substrates with narrow therapeutic index<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Enzalutamide is a strong CYP3A4 inducer &mdash; lowers many drug levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Switch warfarin to a DOAC (apixaban, edoxaban) or monitor INR weekly.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Increased seizure risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid where possible.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Analoga LHRH (goserelin, leuprorelin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Standard background therapy<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Continue throughout enzalutamide treatment.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Skladov\u00e1n\u00ed<\/h2>\n<ul>\n<li>Store at room temperature, 15&ndash;30&deg;C.<\/li>\n<li>Uchov\u00e1vejte mimo dosah d\u011bt\u00ed, \u017een v reproduk\u010dn\u00edm v\u011bku a dom\u00e1c\u00edch zv\u00ed\u0159at.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy na MedsBase<\/h2>\n<p>Dal\u0161\u00ed onkologick\u00e9 l\u00e9ky skladem vedle tohoto produktu:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/bicalumutide\/\"><strong>Bicalumutid (bikalutamid 50 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/cytomid\/\"><strong>Cytomid (flutamide 250 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/cs\/anti-cancer-medication\/\">Prohl\u00e9dn\u011bte v\u0161echny protin\u00e1dorov\u00e9 l\u00e9ky \u2192<\/a><\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Ka\u017ed\u00e1 \u0161ar\u017ee je dod\u00e1v\u00e1na od <strong>v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Objedn\u00e1vky jsou expedov\u00e1ny v nen\u00e1padn\u00fdch obalech bez loga od na\u0161ich partnersk\u00fdch sklad\u016f a jsou pokryty na\u0161\u00ed <a href=\"\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>: pokud z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, za\u0161leme zdarma n\u00e1hradn\u00ed z\u00e1silku, bez dotaz\u016f.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed protin\u00e1dorov\u00e9 l\u00e9ky<\/h3>\n<p>Dal\u0161\u00ed onkologick\u00e9 l\u00e9ky skladem vedle tohoto produktu:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/bicalumutide\/\">Bicalumutid (bikalutamid 50 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/cytomid\/\">Cytomid (flutamide 250 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/endace\/\">Endace (megestrol 40\/160 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tamilong\/\">Tamilong (tamoxifen 10\/20 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/votrient\/\">Votrient (pazopanib 200\/400 mg)<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">How is Bdenza different from bicalutamide or flutamide?<\/h3>\n<p>Enzalutamide is a <strong>second-generation<\/strong> AR signalling inhibitor with three mechanisms (AR binding + AR nuclear translocation block + AR-DNA binding block) versus the single mechanism of first-generation drugs. The clinical implication: <strong>enzalutamide works in castration-resistant disease<\/strong> where bicalutamide and flutamide have failed. It is also more potent and produces deeper PSA responses but with more cognitive side effects, hypertension and fall risk.<\/p>\n<h3 class=\"wp-block-heading\">Why is seizure history a contraindication?<\/h3>\n<p>Enzalutamide crosses the blood-brain barrier and lowers seizure threshold. In trials, seizure incidence was &lt; 1% but increased in patients with predisposing factors. Avoid enzalutamide in any patient with prior seizure (any type), brain metastases, or concurrent drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline). If enzalutamide is essential in such a patient, neurology and oncology specialists must agree on the risk-benefit.<\/p>\n<h3 class=\"wp-block-heading\">Will I have to stop ADT (LHRH agonist) when I start Bdenza?<\/h3>\n<p>No &mdash; continue your LHRH agonist (goserelin, leuprorelin, etc.) throughout enzalutamide treatment. The combination of background castration + AR signalling inhibition is essential. Stopping the LHRH agonist allows testosterone to recover, which can defeat enzalutamide&#39;s effect.<\/p>\n<h3 class=\"wp-block-heading\">Why is fatigue so common on Bdenza?<\/h3>\n<p>Fatigue is the most common and clinically significant side effect &mdash; affecting around 35% of patients in trials. The cause is multifactorial: profound androgen deprivation, possible direct CNS effects, anaemia. Manage with structured exercise (counterintuitively effective), good sleep hygiene, screening and treatment of anaemia, and consideration of dose reduction (160 &rarr; 120 mg\/day) if intolerable.<\/p>\n<h3 class=\"wp-block-heading\">What is PRES and how do I recognise it?<\/h3>\n<p>Posterior reversible encephalopathy syndrome (PRES) is a rare but documented enzalutamide complication characterised by <strong>severe headache, confusion, visual changes (cortical blindness), seizures and altered consciousness<\/strong>. Stop enzalutamide immediately and seek same-day medical review for any of these symptoms. Most cases resolve with drug discontinuation but timely recognition prevents permanent neurological injury.<\/p>\n<h3 class=\"wp-block-heading\">Are there many drug interactions I need to worry about?<\/h3>\n<p>Yes &mdash; enzalutamide is a <strong>strong CYP3A4 inducer<\/strong> and lowers blood levels of many co-prescribed drugs. The most clinically important: <strong>warfarinem<\/strong> (switch to a DOAC or check INR weekly), <strong>direct oral anticoagulants<\/strong> (specialist review), some statins, some antihypertensives, opioids, some antiepileptics. Tell every doctor you are on enzalutamide.<\/p>\n<h3 class=\"wp-block-heading\">Can I drive on Bdenza?<\/h3>\n<p>Caution &mdash; fatigue, dizziness and (rarely) seizures may impair driving. Most patients adapt and drive safely after the first few weeks. Avoid driving or operating machinery if you experience significant fatigue, dizziness, or any cognitive symptoms.<\/p>\n<h3 class=\"wp-block-heading\">Bdenza vs abiraterone &mdash; which is better?<\/h3>\n<p>Both are second-line options after first-generation anti-androgen failure. Head-to-head data is limited; choice depends on side-effect preference and comorbidities. <strong>Enzalutamide:<\/strong> more fatigue, cognitive effects, hypertension, fall risk; no steroid co-prescription needed. <strong>Abiraterone:<\/strong> requires concurrent prednisone 5 mg twice daily; more hypertension and fluid retention; may worsen diabetes control. Discuss with your oncologist.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Slows cancer progression<br \/>\n\u2705 Reduces tumor growth<br \/>\n\u2705 Improves survival outcomes<br \/>\n\u2705 Supports prostate treatment<br \/>\n\u2705 Enhances quality of life<\/p>\n<p><strong>Bdenza<\/strong> obsahuje <strong>Enzalutamide<\/strong> 40 mg.<\/p>","protected":false},"featured_media":67947,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3595],"product_tag":[5422,5423],"class_list":{"0":"post-67946","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_tag-bdenza","8":"product_tag-enzalutamide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/67946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=67946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/67947"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=67946"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=67946"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=67946"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=67946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}